Waterdrop Inc. Reports Second Quarter 2026 Unaudited Financial Results
Waterdrop posted Q2 2026 operating revenue of RMB1,448.2 million, up 72.8% year-over-year, with net profit attributable to ordinary shareholders of RMB125.8 million — its 18th consecutive profitable quarter. The insurance business drove the quarter: insurance-related revenue rose 80.5% YoY and insurance operating profit reached RMB183.6 million, up 20% QoQ. The company launched Rongyibao, the market's first no-health-disclosure long-term critical illness product, and expanded the Jixing Gaozhao lifetime specified disease line.
Key figures
- Revenue
- RMB1,448.2 million
- Revenue Yoy
- 72.8%
- Efind revenue rmb
- 35200000
- Efind revenue yoy
- 26.8%
- Insurance revenue yoy
- 80.5%
- Efind pharma cro partners
- 255
- Ads repurchased cumulative
- approximately 62.9 million
- Ai expert premium growth qoq
- 25.6%
- Crowdfunding patients helped
- 3.82 million
- Crowdfunding cumulative donors
- approximately 499 million
- Insurance operating profit qoq
- 20%
- Insurance operating profit rmb
- 183600000
- Ai fundraising assistant cities
- 548
- Consecutive profitable quarters
- 18
- Efind enrolled patients cumulative
- 17052
- Crowdfunding cumulative donations rmb
- 74.7 billion
- First year long term premium growth qoq
- 33.4%
- Efind clinical trial projects cumulative
- 1873
- Net profit attributable to shareholders rmb
- 125800000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.